fda status bpc-157 compounding 2026 panel backs compounded BPC-157, KPV peptides in win for RFK Jr 3 FOR 3. An FDA

3 FOR 3. An FDA advisory committee has now voted 86, with one abstention, to recommend BPC 157, KPV and TB 500 for inclusion on the 503A Bulks List. This is not FDA approval FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them FDA to Reconsider BPC 157 and Other Peptides Ashish Talati posted on the topic LinkedIn FDA Peptide Reclassification 2026: What It Means for Providers

SKU: 70653009178 · From www.asociacionchamorro.org